Trial Profile
A Multicentre,Randomised, Double-blind, Placebo-controlled, 3-arm, 24-week Parallel-group Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of ORY-2001 in Patients With Mild-moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Vafidemstat (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms ETHERAL-US
- Sponsors Oryzon
- 09 Mar 2021 Results published in the Oryzon Media Release.
- 09 Mar 2021 According to an Oryzon media release, new data from this study will be presented today at the 15th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, AD/PD-2021.
- 04 Mar 2021 Status changed from active, no longer recruiting to completed.